Pipeline Insight: Cancer Overview
Gastrointestinal, Skin, Sarcomas
| Product Code | DAT08935 |
| Publication Date | January 2009 |
| Publisher | Datamonitor |
| Product Type | Report |
| Pages | 265 |
| ISBN Number | not applicable |
Pipeline Insight: Cancer Overview
Gastrointestinal, Skin, Sarcomas
Introduction
In 2008, the six tumor types covered in this report are forecast to account for over 961,000 new cases of cancer. Collectively, the 32 different drugs in Phase III development for the six tumor types are forecast to achieve $4,789m in sales by 2017. This constitutes a significant proportion of the oncology market, thus representing ample commercial opportunities for drug developers.
Scope
- Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor types
- Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2017 with product-specific assumptions
- Segmentation and analysis of the current solid tumor pipeline by developmental phase, drug class and indication for six tumor types
- Insight and analysis of market potential including commercial opportunity, epidemiology, commonalities across cancers and discussion of unmet needs
Highlights
- Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) and brivanib (BMS-582664; Bristol-Myers Squibb) show the most potential in the colorectal cancer pipeline. Aflibercept has shown activity following failure of prior standard Avastin (bevacizumab; Genentech/Roche), while brivanib's novel mechanism of action could represent a first-in-class therapy.
- Melanoma is the most popular R&D target of the six tumor types covered in this report, due to persistent high unmet needs and a substantial incidence. Elesclomol (STA-4783; Synta Pharmaceuticals/GlaxoSmithKline) currently shows the most potential at present, although only if successful Phase II results can be replicated in Phase III studies.
- First-line axitinib (AG-13736; Pfizer) and Gemzar (gemcitabine; Eli Lilly) showed similar response rates and overall survival to first-line Gemzar and Tarceva (erlotinib; Genentech/Roche) in pancreatic cancer. If this can be replicated in Phase III trials, approval is likely, given that Tarceva was approved based on a 2-week survival benefit.
Reasons to Purchase
- Identify key drugs and companies within the oncology pipeline based on sales forecasts to 2017 and Datamonitor drug assessment
- Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline products to fulfil them
- Assess the shifting oncology market dynamic and how future treatment of solid tumors will incorporate pipeline products
Contents
- Chapter 1 Executive Summary
- Scope of the analysis
- Datamonitor insight into the cancer market
- Related reports
- Upcoming reports
- Chapter 2 Pipeline Overview and Dynamics
- Pipeline overview
- Late-phase pipeline
- Pipeline by indication
- Melanoma emerges as the most popular R&D target, due to a significant level of unmet need which could result in high commercial reward
- Chapter 3 R&d Approach
- Classification of pipeline products
- Cytotoxics
- Molecular targeted therapies
- Immunotherapeutic agents
- Oncology clinical trial design
- Chapter 4 Colorectal Cancer
- Overview of colorectal cancer
- Definition
- Colorectal cancer is the third most common tumor type and cause of cancer-related death in both men and women
- Epidemiology
- Incidence continues to rise with an increase in prevalence of risk factors and the aging population
- Mortality from colorectal cancer is relatively high due to a tendency for later diagnosis
- Treatment of colorectal cancer
- Unmet need in colorectal cancer
- Summary of unmet needs
- Lack of identifiable risk factors and effective screening tools
- Prognosis remains poor, despite significant advances in therapy
- A high rate of disease recurrence illustrates the need for more effective therapies
- Pipeline overview
- Definition of current comparator therapy
- Pipeline summary
- Late-phase pipeline
- Phase II pipeline
- Comparative forecasts
- Pipeline candidates
- Afinitor (everolimus; Novartis)
- Drug overview
- Key historical events
- Clinical development in colorectal cancer
- Datamonitor comments
- Recentin (cediranib; AstraZeneca)
- Drug overview
- Key historical events
- Clinical development in colorectal cancer
- Datamonitor comments
- Sutent (sunitinib; Pfizer)
- Drug overview
- Key historical events
- Clinical development in colorectal cancer
- Datamonitor comments
- Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis)
- Drug overview
- Key historical events
- Clinical development in colorectal cancer
- Datamonitor comments
- Brivanib (BMS-582664; Bristol-Myers Squibb)
- Drug overview
- Key historical events
- Clinical development in colorectal cancer
- Datamonitor comments
- Davanat (carbohydrate polymer drug delivery system; Pro-Pharmaceuticals)
- Drug overview
- Key historical events
- Clinical development in colorectal cancer
- Datamonitor comments
- Satisfaction of unmet needs
- Aflibercept and brivanib could eventually provide effective alternative therapies in metastatic colorectal cancer
- Chapter 5 Gastric Cancer
- Overview of gastric cancer
- Definition
- Gastric cancer is the second most common tumor type on a global scale
- Epidemiology
- despite a worldwide decline in incidence, gastric cancer remains a major health burden
- Mortality is a greater concern in the US and Western Europe
- Treatment of gastric cancer
- Unmet need in gastric cancer
- Summary of unmet needs
- Lack of effective systemic therapy
- Poorly defined standard treatment regimens
- Poor control of distant metastases
- Complete lack of second-line options
- Pipeline overview
- Definition of current comparator therapy
- Pipeline summary
- Late-phase pipeline
- Phase II pipeline
- Comparative forecasts
- Pipeline candidates
- Avastin (bevacizumab; Genentech/Roche/Chugai)
- Drug overview
- Key historical events
- Clinical development in gastric cancer
- Datamonitor comments
- Erbitux (cetuximab; ImClone/Bristol-Myers Squibb/Merck Serono)
- Drug overview
- Key historical events
- Clinical development in gastric cancer
- Datamonitor comments
- Tykerb (lapatinib; GlaxoSmithKline)
- Drug overview
- Key historical events
- Clinical development in gastric cancer
- Datamonitor comments
- Satisfaction of unmet needs
- The three targeted therapies in late-phase development for gastric cancer show promise in fulfilling unmet need if certain hurdles can be overcome
- Chapter 6 Hepatocellular Carcinoma
- Overview of hepatocellular carcinoma
- Definition
- Hepatitis is a known risk factor for hepatocellular carcinoma
- Epidemiology
- Japan accounts for nearly half of all new hepatocellular carcinoma cases in the seven major markets due to a high prevalence of hepatitis
- Mortality from hepatocellular carcinoma is high, although prognosis is steadily improving
- Treatment of hepatocellular carcinoma
- Unmet need in hepatocellular carcinoma
- Summary of unmet needs
- Better systemic therapy is required
- Clinical trials are currently poorly designed
- HCC suffers from a relatively modest R&D interest
- Pipeline overview
- Definition of current comparator therapy
- Pipeline summary
- Late-phase pipeline
- Phase II pipeline
- Comparative forecasts
- Pipeline candidates
- Sutent (sunitinib; Pfizer)
- Drug overview
- Key historical events
- Clinical development in hepatocellular carcinoma
- Datamonitor comments
- ThermoDox (heat-activated doxorubicin; Celsion)
- Drug overview
- Key historical events
- Clinical development in hepatocellular carcinoma
- Datamonitor comments
- Miriplatin (SM-11355; Dainippon Sumitomo)
- Drug overview
- Key historical events
- Clinical development in hepatocellular carcinoma
- Datamonitor comments
- Litx (talaporfin; Light Sciences Oncology)
- Drug overview
- Key historical events
- Clinical development in hepatocellular carcinoma
- Datamonitor comments
- Satisfaction of unmet needs
- Sutent could provide an effective alternative to Nexavar, however, the remaining pipeline drugs face significant barriers to market entry
- Chapter 7 Melanoma
- Overview of melanoma
- Definition
- Melanoma is the least common type of skin cancer, although the most potentially fatal
- Epidemiology
- Incidence of melanoma will continue to rise due to increasing exposure of the population to UV light
- Mortality from melanoma is relatively low in comparison to its incidence due to a high rate of early diagnosis
- Treatment of melanoma
- Unmet need in melanoma
- Summary of unmet needs
- Current therapeutics have a high risk-to-benefit ratio
- over the past three decades there have been few significant advances in drug therapy for metastatic disease
- Early diagnosis is the key to curative treatment
- Gene profiling will help individualize treatment approaches
- Pipeline overview
- Definition of current comparator therapy
- Pipeline summary
- Late-phase pipeline
- Phase II pipeline
- Comparative forecasts
- Pipeline candidates
- Genasense (oblimersen; Genta)
- Drug overview
- Key historical events
- Clinical development in melanoma
- Datamonitor comments
- Elesclomol (STA-4783; Synta/GlaxoSmithKline)
- Drug overview
- Key historical events
- Clinical development in melanoma
- Datamonitor comments
- Taxoprexin (DHA paclitaxel; Luitpold Pharmaceutical)
- Drug overview
- Key historical events
- Clinical development in melanoma
- Datamonitor comments
- PEG-Intron (pegylated interferon-alpha; Schering-Plough)
- Drug overview
- Key historical events
- Clinical development in melanoma
- Datamonitor comments
- Ipilimumab (MDX-010; Medarex/Bristol-Myers Squibb)
- Drug overview
- Key historical events
- Clinical development in melanoma
- Datamonitor comments
- MDX-1379 (Medarex/Bristol-Myers Squibb)
- Drug overview
- Key historical events
- Clinical development in melanoma
- Datamonitor comments
- Allovectin-7 (velimogene aliplasmid; Vical)
- Drug overview
- Key historical events
- Clinical development in melanoma
- Datamonitor comments
- Satisfaction of unmet needs
- The late-phase targeted therapies are most likely to fulfill unmet needs in melanoma, however, only if certain issues can be overcome
- Chapter 8 Pancreatic Cancer
- Overview of pancreatic cancer
- Definition
- Pancreatic cancer represents a major health issue in the developed world
- Epidemiology
- Incidence of pancreatic cancer will continue to rise as a reflection of the aging population
- Mortality from pancreatic cancer is nearly equal to its incidence
- Treatment of pancreatic cancer
- Unmet need in pancreatic cancer
- Summary of unmet need
- Associated with exceptionally poor survival rates
- Earlier rates of diagnosis are desperately needed in order to boost survival
- A lack of effective systemic therapies exists, therefore an higher level of R&D interest is needed
- Pipeline overview
- Definition of current comparator therapy
- Pipeline summary
- Late-phase pipeline
- Phase II pipeline
- Comparative forecasts
- Pipeline candidates
- Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis)
- Drug overview
- Key historical events
- Clinical development in pancreatic cancer
- Datamonitor comments
- Axitinib (AG-13736; Pfizer)
- Drug overview
- Key historical events
- Clinical development in pancreatic cancer
- Datamonitor comments
- Larotaxel (XRP-9881; Sanofi-Aventis)
- Drug overview
- Key historical events
- Clinical development in pancreatic cancer
- Datamonitor comments
- GV-1001 (tertomotide; Pharmexa)
- Drug overview
- Key historical events
- Clinical development in pancreatic cancer
- Datamonitor comments
- TNFerade (TNF-alpha gene therapy; GenVec)
- Drug overview
- Key historical events
- Clinical development in pancreatic cancer
- Datamonitor comments
- Satisfaction of unmet needs
- Axitinib could fulfill some unmet needs in pancreatic cancer, however, the remaining pipeline drugs are difficult to judge due to a lack of clinical data or the significant hurdles they face
- Chapter 9 Sarcoma
- Overview of sarcoma
- Definition
- Sarcomas represent a diverse group of malignancies
- Epidemiology
- The diversity and rarity of sarcomas makes it difficult to determine incidence
- Evolution of multimodality treatment for sarcomas of the bone has improved survival, while early diagnosis of soft tissue sarcoma allows for relatively high survival
- Treatment of sarcoma
- Sarcoma of the bone
- Soft tissue sarcoma
- Unmet need in sarcoma
- Summary of unmet need
- Better classification methods are needed
- Greater range of treatment options following surgery and more efficacious agents for advanced disease are necessary
- Pipeline overview
- Definition of current comparator therapy
- Pipeline summary
- Late-phase pipeline
- Phase II pipeline
- Comparative forecasts
- Pipeline candidates
- Avastin (bevacizumab; Genentech/Roche)
- Drug overview
- Key historical events
- Clinical development in sarcoma
- Datamonitor comments
- Tasigna (nilotinib; Novartis)
- Drug overview
- Key historical events
- Clinical development in sarcoma
- Datamonitor comments
- Deforolimus (AP-23573; ARIAD/Merck & Co)
- Drug overview
- Key historical events
- Clinical development in sarcoma
- Datamonitor comments
- Retaspimycin (IPI-504; Infinity/MedImmune)
- Drug overview
- Key historical events
- Clinical development in sarcoma
- Datamonitor comments
- Ombrabulin (AVE-8062; Sanofi-Aventis/Ajinomoto)
- Drug overview
- Key historical events
- Clinical development in sarcoma
- Datamonitor comments
- Mepact (liposomal mifamurtide; IDM Pharma)
- Drug overview
- Key historical events
- Clinical development in sarcoma
- Datamonitor comments
- Satisfaction of unmet needs
- Tasigna shows great potential to fulfill unmet needs in the third-line GIST setting, while deforolimus could provide an effective therapy in the maintenance setting for metastatic soft tissue and bone sarcoma
- Appendix A
- Bibliography
- List of tables
- List of figures
- List of abbreviations
- Contributing experts
- Methodology
- Datamonitor forecast methodology
- Epidemiology forecasts
- Product forecasts
- Datamonitor drug assessment summary
- Appendix B
- about Datamonitor
- about Datamonitor Healthcare
- Datamonitor Healthcare's therapy area capabilities
- about the Disease analysis team
- Disclaimer
- List of Tables
- Table 1: Late-phase cytotoxics pipeline for colorectal cancer, gastric cancer, hepatocellular carcinoma, melanoma, pancreatic cancer and sarcoma, 2008
- Table 2: Late-phase immunotherapies pipeline for colorectal cancer, gastric cancer, hepatocellular carcinoma, melanoma, pancreatic cancer and sarcoma, 2008
- Table 3: Late-phase gene and photodynamic therapies pipeline for colorectal cancer, gastric cancer, hepatocellular carcinoma, melanoma, pancreatic cancer and sarcoma, 2008
- Table 4: Late-phase targeted therapies pipeline for colorectal cancer, gastric cancer, hepatocellular carcinoma, melanoma, pancreatic cancer and sarcoma, 2008
- Table 5: Pipeline split by developmental phase and indication, 2008
- Table 6: Cytotoxic subgroup mechanisms of action
- Table 7: Targeted therapy subgroup mechanisms of action
- Table 8: Immunotherapy subgroup mechanisms of action
- Table 9: Oncology clinical trial design factors
- Table 10: Forecast incidence of colorectal cancer in the seven major pharmaceutical markets, 2002-2017
- Table 11: Avastin: key facts, 2008
- Table 12: Phase III colorectal cancer pipeline, 2008
- Table 13: Phase II colorectal cancer pipeline, 2008 (targeted therapies)
- Table 14: Phase II colorectal cancer pipeline, 2008 (cytotoxics)
- Table 15: Phase II colorectal cancer pipeline, 2008 (miscellaneous)
- Table 16: Forecasting assumptions for colorectal cancer pipeline products across the seven major markets, 2008 (1 of 2)
- Table 17: Forecasting assumptions for colorectal cancer pipeline products across the seven major markets, 2008 (2 of 2)
- Table 18: Pipeline colorectal cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 19: Afinitor: key historical events
- Table 20: Clinical development of Afinitor in colorectal cancer, 2008
- Table 21: Recentin: key historical events
- Table 22: Clinical development of Recentin in colorectal cancer, 2008
- Table 23: Sutent: key historical events
- Table 24: Clinical development of Sutent in colorectal cancer, 2008
- Table 25: Aflibercept: key historical events
- Table 26: Clinical development of aflibercept in colorectal cancer, 2008
- Table 27: Brivanib: key historical events
- Table 28: Clinical development of brivanib in colorectal cancer, 2008
- Table 29: Phase I results investigating a second-line or higher combination of Erbitux and brivanib in advanced gastrointestinal malignancies
- Table 30: Davanat: key historical events
- Table 31: Clinical development of Davanat in colorectal cancer, 2008
- Table 32: Fulfillment of unmet needs by pipeline colorectal cancer drugs, 2008
- Table 33: Crude incidence rates of gastric cancer by gender per 100,000 in the seven major pharmaceutical markets, 2002
- Table 34: Forecast incidence of gastric cancer in the seven major pharmaceutical markets, 2002-2017
- Table 35: Five-year survival rates by stage for gastric cancer in the US and Japan
- Table 36: Taxotere: key facts, 2008
- Table 37: Phase III gastric cancer pipeline, 2008
- Table 38: Phase II gastric cancer pipeline, 2008 (targeted therapies)
- Table 39: Phase II gastric cancer pipeline, 2008 (cytotoxics and immunotherapies)
- Table 40: Forecasting assumptions for gastric cancer pipeline products across the seven major markets, 2008
- Table 41: Pipeline gastric cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 42: Avastin: key historical events
- Table 43: Clinical development of Avastin in gastric cancer, 2008
- Table 44: Erbitux: key historical events
- Table 45: Clinical development of Erbitux in gastric cancer, 2008
- Table 46: Tykerb: key historical events
- Table 47: Clinical development of Tykerb in gastric cancer, 2008
- Table 48: Fulfillment of unmet needs by pipeline gastric cancer drugs, 2008
- Table 49: Forecast incidence of hepatocellular carcinoma in the seven major pharmaceutical markets, 2002-2017
- Table 50: Nexavar: key historical facts
- Table 51: Phase III hepatocellular carcinoma pipeline, 2008
- Table 52: Phase II hepatocellular carcinoma pipeline, 2008 (targeted therapies)
- Table 53: Phase II hepatocellular carcinoma pipeline, 2008 (cytotoxics)
- Table 54: Phase II hepatocellular carcinoma pipeline, 2008 (immunotherapies)
- Table 55: Forecasting assumptions for hepatocellular carcinoma pipeline products across the seven major markets, 2008 (1 of 2)
- Table 56: Forecasting assumptions for hepatocellular carcinoma pipeline products across the seven major markets, 2008 (2 of 2)
- Table 57: Pipeline hepatocellular carcinoma product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 58: Sutent: key historical events
- Table 59: Clinical development of Sutent in hepatocellular carcinoma, 2008
- Table 60: ThermoDox: key historical events
- Table 61: Clinical development of ThermoDox in hepatocellular carcinoma, 2008
- Table 62: Miriplatin: key historical events
- Table 63: Litx: key historical events
- Table 64: Clinical development of Litx in hepatocellular carcinoma, 2008
- Table 65: Fulfillment of unmet needs by pipeline hepatocellular carcinoma drugs, 2008
- Table 66: Forecast incidence of melanoma in the seven major pharmaceutical markets, 2002-2017
- Table 67: Stage distribution of melanoma in the US, 1975-2000
- Table 68: Five-year survival rates by pathologic stage for melanoma, 2001
- Table 69: Temodar: key facts
- Table 70: Phase III melanoma pipeline, 2008
- Table 71: Phase II melanoma pipeline, 2008 (targeted therapies)
- Table 72: Phase II melanoma pipeline, 2008 (cytotoxics)
- Table 73: Phase II melanoma pipeline, 2008 (immunotherapies)
- Table 74: Phase II melanoma pipeline, 2008 (miscellaneous)
- Table 75: Forecasting assumptions for melanoma pipeline products across the seven major markets, 2008 (1 of 2)
- Table 76: Forecasting assumptions for melanoma pipeline products across the seven major markets, 2008 (2 of 2)
- Table 77: Pipeline melanoma product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 78: Genasense: key historical events
- Table 79: Clinical development of Genasense in melanoma, 2008
- Table 80: Elesclomol: key historical events
- Table 81: Clinical development of elesclomol in melanoma, 2008
- Table 82: Survival analysis of Phase II study of elesclomol + paclitaxel in metastatic melanoma
- Table 83: Taxoprexin: key historical events
- Table 84: Clinical development of Taxoprexin in melanoma, 2008
- Table 85: PEG-Intron: key historical events
- Table 86: Clinical development of PEG-Intron in melanoma, 2008
- Table 87: Ipilimumab: key historical events
- Table 88: Clinical development of ipilimumab in melanoma, 2008
- Table 89: MDX-1379: key historical events
- Table 90: Clinical development of MDX-1379 in melanoma, 2008
- Table 91: Allovectin-7: key historical events
- Table 92: Clinical development of Allovectin-7 in melanoma, 2008
- Table 93: Fulfillment of unmet needs by pipeline melanoma drugs, 2008
- Table 94: Forecast incidence of pancreatic cancer in the seven major pharmaceutical markets, 2002-2017
- Table 95: Gemzar: key facts
- Table 96: Phase III pancreatic cancer pipeline, 2008
- Table 97: Phase II pancreatic cancer pipeline, 2008 (targeted therapies)
- Table 98: Phase II pancreatic cancer pipeline, 2008 (cytotoxics)
- Table 99: Phase II pancreatic cancer pipeline, 2008 (miscellaneous)
- Table 100: Forecasting assumptions for pancreatic cancer pipeline products across the seven major markets, 2008 (1 of 2)
- Table 101: Forecasting assumptions for pancreatic cancer pipeline products across the seven major markets, 2008 (2 of 2)
- Table 102: Pipeline pancreatic cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 103: Aflibercept: key historical events
- Table 104: Clinical development of aflibercept in pancreatic cancer, 2008
- Table 105: Axitinib: key historical events
- Table 106: Clinical development of axitinib in pancreatic cancer, 2008
- Table 107: Larotaxel: key historical events
- Table 108: Clinical development of larotaxel in pancreatic cancer, 2008
- Table 109: GV-1001: key historical events
- Table 110: Clinical development of GV-1001 in pancreatic cancer, 2008
- Table 111: TNFerade: key historical events
- Table 112: Clinical development of TNFerade in pancreatic cancer, 2008
- Table 113: Fulfillment of unmet needs by pipeline pancreatic cancer drugs, 2008
- Table 114: Types of sarcoma of the bone
- Table 115: Proportion of soft tissue sarcomas based on site of malignancy
- Table 116: Forecast incidence of sarcoma in the seven major pharmaceutical markets, 2002-2017
- Table 117: Forecast incidence of soft tissue sarcoma in the seven major pharmaceutical markets, 2002-2017
- Table 118: Forecast incidence of gastrointestinal stromal tumors in the seven major pharmaceutical markets, 2002-2017
- Table 119: Forecast incidence of osteosarcoma in the seven major pharmaceutical markets, 2002-2017
- Table 120: Five-year survival rates by stage of soft tissue sarcoma
- Table 121: Gleevec: key facts
- Table 122: Phase III sarcoma pipeline, 2008
- Table 123: Phase II sarcoma pipeline, 2008 (targeted therapies)
- Table 124: Phase II sarcoma pipeline, 2008 (cytotoxics)
- Table 125: Phase II sarcoma pipeline, 2008 (miscellaneous)
- Table 126: Forecasting assumptions for sarcoma pipeline products across the seven major markets, 2008 (1 of 2)
- Table 127: Forecasting assumptions for sarcoma pipeline products across the seven major markets, 2008 (2 of 2)
- Table 128: Pipeline sarcoma product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 129: Avastin: key historical events
- Table 130: Clinical development of Avastin in sarcoma, 2008
- Table 131: Tasigna: key historical events
- Table 132: Clinical development of Tasigna in gastrointestinal stromal tumors , 2008
- Table 133: Deforolimus: key historical events
- Table 134: Clinical development of deforolimus in sarcoma, 2008
- Table 135: Retaspimycin: key historical events
- Table 136: Clinical development of retaspimycin in sarcoma, 2008
- Table 137: Phase I trial results investigating retaspimycin in GIST and other soft tissue sarcomas
- Table 138: Ombrabulin: key historical events
- Table 139: Clinical development of ombrabulin in soft tissue sarcoma, 2008
- Table 140: Mepact: key historical events
- Table 141: Clinical development of Mepact in osteosarcoma, 2008
- Table 142: Updated overall survival results from the Phase III INT-0133 study
- Table 143: Fulfillment of unmet needs by pipeline sarcoma drugs, 2008
- Table 144: List of abbreviations
- Table 145: Datamonitor drug assessment parameters
- List of Figures
- Figure 1: Forecast incidence and mortality from colorectal cancer in 2008 and 2017 across the seven major markets
- Figure 2: Improving survival in colorectal cancer with newer drug regimens
- Figure 3: Summary of unmet needs in the colorectal cancer market, 2008
- Figure 4: Datamonitor drug assessment summary for the pipeline colorectal cancer products, 2008
- Figure 5: Pipeline colorectal cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 6: Phase II results for second-line FOLFOX + Recentin versus FOLFOX + Avastin in metastatic colorectal cancer
- Figure 7: Phase II results investigating second-line or higher Sutent in metastatic colorectal cancer after failure of standard therapy
- Figure 8: Phase II results investigating second-line or higher aflibercept in metastatic colorectal cancer after failure of standard therapy
- Figure 9: Phase II DAVFU-003 results investigating third/fourth-line Davanat + 5-fluorouracil in recurrent metastatic colorectal cancer
- Figure 10: Interim Phase II DAVFU-006 results investigating first-line Davanat, 5-fluorouracil, leucovorin + Avastin in advanced colorectal cancer
- Figure 11: Forecast incidence and mortality from gastric cancer in 2008 and 2017 across the seven major markets
- Figure 12: Gastric cancer treatment options, 2008
- Figure 13: Summary of unmet needs in the gastric cancer market, 2008
- Figure 14: Datamonitor drug assessment summary for the pipeline gastric cancer products, 2008
- Figure 15: Pipeline gastric cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 16: Phase II results for first-line Avastin, Taxotere and Eloxatin in locally advanced or metastatic gastric cancer
- Figure 17: Phase II results for first-line Avastin, Camptosar and cisplatin in metastatic gastric cancer
- Figure 18: Phase II results for first-line Avastin and Taxotere in metastatic gastric cancer
- Figure 19: Phase II results for first-line Erbitux, Xeloda and cisplatin in advanced gastric cancer
- Figure 20: Phase II results for first-line Erbitux, Taxotere and cisplatin in locally advanced or metastatic gastric cancer
- Figure 21: Phase II results for second-line Erbitux and Taxotere in Taxotere-refractory metastatic gastric cancer
- Figure 22: Phase II results for first-line Tykerb in advanced gastric cancer
- Figure 23: Five-year survival rates for liver and intrahepatic bile duct cancer, 1975-1998
- Figure 24: Hepatocellular carcinoma treatment options, 2008
- Figure 25: Summary of unmet needs in the hepatocellular carcinoma market, 2008
- Figure 26: Datamonitor drug assessment summary for the pipeline hepatocellular carcinoma products, 2008
- Figure 27: Pipeline hepatocellular carcinoma product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 28: Phase II results investigating first/second-line single-agent Sutent in unresectable or metastatic hepatocellular carcinoma
- Figure 29: Preliminary Phase II results investigating first-line single-agent Sutent in unresectable or metastatic hepatocellular carcinoma
- Figure 30: Phase II results investigating first-line miriplatin in chemotherapy-nave hepatocellular carcinoma
- Figure 31: Forecast incidence and mortality from melanoma in 2008 and 2017 across the seven major markets
- Figure 32: Melanoma treatment options, 2008
- Figure 33: Summary of unmet needs in the melanoma market, 2008
- Figure 34: Datamonitor drug assessment summary for the pipeline melanoma products, 2008
- Figure 35: Pipeline melanoma product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 36: Long-term follow-up results from a Phase III trial investigating first-line dacarbazine with or without Genasense in metastatic melanoma
- Figure 37: Randomized Phase II trial results investigating a first/second-line combination of paclitaxel and elesclomol in Stage IV melanoma patients
- Figure 38: Phase II results investigating first-line weekly Taxoprexin in metastatic melanoma
- Figure 39: Phase II results investigating first-line 3-weekly Taxoprexin in metastatic melanoma
- Figure 40: Phase III results investigating adjuvant PEG-Intron versus observation in resected Stage III melanoma
- Figure 41: Phase II results investigating first-line ipilimumab with or without dacarbazine in advanced melanoma
- Figure 42: Phase II results investigating varying doses of first-line ipilimumab in unresectable Stage III/IV melanoma patients
- Figure 43: Analysis of data from five Phase I/II clinical trials investigating ipilimumab in Stage III/IV melanoma
- Figure 44: Phase II trial results investigating a second-line combination of ipilimumab and MDX-1379 in Stage IV melanoma patients
- Figure 45: Phase II results investigating high-dose Allovectin-7 in recurrent or unresponsive Stage III/IV melanoma
- Figure 46: Forecast incidence and mortality from pancreatic cancer in 2008 and 2017 across the seven major markets
- Figure 47: Pancreatic cancer treatment options, 2008
- Figure 48: Summary of unmet needs in the pancreatic cancer market, 2008
- Figure 49: Datamonitor drug assessment summary for the pipeline pancreatic cancer products, 2008
- Figure 50: Pipeline pancreatic cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 51: Randomized Phase II trial investigating first-line Gemzar with or without axitinib in advanced pancreatic cancer
- Figure 52: Phase I/II trial results investigating GV-1001 in unresectable pancreatic cancer
- Figure 53: Interim results from the Phase III PACT trial
- Figure 54: Summary of unmet needs in the sarcoma market
- Figure 55: Datamonitor drug assessment summary for the pipeline sarcoma products, 2008
- Figure 56: Pipeline sarcoma product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 57: Phase I/II results investigating first-line Avastin, Taxotere and Gemzar in advanced or recurrent soft tissue sarcoma
- Figure 58: Phase I trial investigating second-line Tasigna alone or in combination with Gleevec in Gleevec-resistant GIST patients
- Figure 59: Phase II results investigating first-line deforolimus in unresectable and/or metastatic soft tissue and bone sarcoma patients
- Figure 60: Phase III INT-0133 study design
- Figure 61: Phase III INT-0133 results investigating neoadjuvant and adjuvant standard chemotherapy + Mepact in newly diagnosed, resectable osteosarcoma
- Figure 62: Datamonitor drug assessment summary of pipeline molecular targeted therapies in development for hematological malignancies, 2007